LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery (NCT05879432)
Phase 2 Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of LSALT Peptide for the Prevention or Attenuation of Acute Kidney Injury (AKI) in Patients Undergoing On-Pump Cardiac Surgery
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the percentage of subjects with AKI within 7 days following on-pump cardiac surgery defined by the KDIGO (Kidney Disease: Improving Global Outcomes) criteria: 1. Increase in baseline (pre-surgery) serum creatinine (SCr) by ≥26.5 μmol/L (≥0.3 mg/dL) within 7 days; OR 2. Increase in baseline SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the first 7 days following surgery; OR 3. Urine output \< 0.5 mL/kg/h for \>6 hours.
Who can join: Review the eligibility criteria below.
Location: Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Cumming School of Medicine & Libin Cardiovascular Centre, University of Calgary — Calgary, Alberta
- Royal Columbian Hospital — New Westminster, British Columbia
- Unity Health Toronto, St. Michael's Hospital — Toronto, Ontario
- University Health Network, Toronto General Hospital — Toronto, Ontario
- Gazi University — Yenimahalle, Ankara
- Kosuyolu High Specialization Training and Research Hospital — Kartal, Istanbul
- Erciyes University, Faculty of Medicine - Semiha Kibar Organ Transplant & Dialysis Hospital — Melikgazi, Kayseri
- Kocaeli University, Faculty of Medicine Practices and Research Hospital — İzmit, Kocaeli
- Sütçü İmam University, Faculty of Medicine — Kahramanmaraş, Onikişubat
📞 Contact the Study Coordinator
Phone: (647) 428-7031
Email: rm@archbiopartners.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Kidney Injury
- An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury — Chicago, Illinois
- Acute Kidney Injury Genomics and Biomarkers in TAVR Study — Dallas, Texas
- Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury — Boston, Massachusetts
- Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage — Oklahoma City, Oklahoma
- Proactive Prescription-based Fluid Management vs Usual Care in Critically Ill Patients on Kidney Replacement Therapy — Montreal, Quebec
- A Study of Auxora in Patients With AKI and Injurious Lung "Crosstalk" — Birmingham, Alabama
Explore by condition: All Acute Kidney Injury clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.